In patients with Type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD), tirzepatide was non‑inferior to dulaglutide for major cardiovascular events while providing superior kidney protection, lower all‑cause mortality, and greater reductions in HbA1c and body weight. Compared with dulaglutide, a GLP‑1 receptor agonist, tirzepatide demonstrated broader metabolic and clinical benefits. By using dulaglutide as the active comparator rather than a placebo, the trial demonstrated tirzepatide’s strong cardiovascular and metabolic profile, supporting its potential for broader use beyond diabetes management.

In this interview, Dipti Itchhaporia MD, MACC and Stephen Nicholls, MBBS, PhD, FACC discuss the SURPASS-CVOT Trial (Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events).

Related References:

1. 1. Nicholls SJ, Bhatt DL, Buse JB, et al. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart J. 2024;267:1-11. doi:10.1016/j.ahj.2023.09.007